Eight Years Into the AI Drug Discovery Boom, No AI-Designed Medicine Has Been Approved

Nearly eight years into the AI drug discovery boom, no medicine discovered or designed with AI has been approved by a regulator in any major market — despite roughly $60 billion invested since 2019 and somewhere between 117 and 175 AI-enabled drug programs having entered human clinical trials, depending on which tracker's methodology is used.

Why This Isn't Necessarily a Failure Story

Drug development timelines are famously long even without AI involvement — a decade-plus from discovery to approval is normal for conventional drug development, and AI-discovered candidates are still working through the same lengthy, safety-driven regulatory trial process, not a shortcut around it. Eight years of AI-assisted discovery work having produced 117-175 human trial programs but zero approvals yet is arguably consistent with normal pharmaceutical timelines, not evidence AI drug discovery specifically has underperformed.

• $60 billion invested with zero approved products is a genuinely long patience horizon for any other technology category — pharma's regulatory reality is a real, industry-specific reason ROI timelines here look nothing like typical enterprise AI adoption
• The EU AI Act's high-risk classification, effective August 2, 2026, may now also apply to some drug-development AI systems specifically, adding a new compliance dimension to an already long development timeline
• The FDA's draft AI guidance, expected to be finalized in 2026, will require sponsors to develop credibility assessment plans for high-risk AI applications in drug development — a concrete near-term regulatory milestone actually worth tracking, separate from the approval-timeline question